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of optic nerve thickening with enhancement and calcification within the tumor was not seen; instead, an elongating gadolinium
enhancing band-like area adjacent to the superomedial aspect of the left optic nerve sheath was identified. The diagnosis was
confirmed on histopathology. Our report adds to the spectrum of presentations of this relatively common clinical entity.
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Optic nerve sheath meningiomas (ONSM) account for 2%
of all orbital tumors.1 They are the second most common
optic nerve tumor after gliomas and represent 1–2% of all
meningiomas.2,3 Without treatment, continued growth of
ONSM results in progressive loss of visual acuity, color
blindness and eventually complete loss of vision.1 No
tumor-related deaths have been reported.3 Radiological
findings are usually of an enlarged optic canal, optic nerve
thickening and enhancement and calcification within the
tumor.2 Definitive treatment of ONSM is controversial.
Fractionated radiotherapy is often first choice in an attempt
to control the ONSM growth rate and to preserve vision if
the diagnosis is not in question.3 Surgery remains best-
treatment in cases with blindness, severe proptosis and in
patients with intracranial extension.3Case report
A 57-year-old female doctor presented with a 1-year his-
tory of blurred vision and visual field changes in her left
eye. She had a history of a pituitary adenoma 30 years
previously, treated by open craniotomy and post-operative
radiotherapy (4200 rad over 20 treatments). She was
otherwise well.
Examination revealed visual acuity of 20/17 on the right
and 20/120 on the left. There was left relative afferent
pupillary defect and left sided brightness desaturation. No
proptosis was noted and the patient had a full range of ocular
movements. Anterior segment examination was unremark-
able, while fundal examination showed disk pallor of the left
optic nerve head without disk swelling. There was progres-
sion of inferior visual field loss (Humphrey Field Analyzer;
Zeiss, Germany) between January 2010 and February 2011
as shown in Fig. 1.e:
al.com
Figure 1. Humphrey visual field of the left eye. Clear progression is visible with inferior visual field involvement over a year.
Figure 2. T1 weighted magnetic resonance image with gadolinium enhancement of the optic nerve sheath meningioma (A) transverse view, (B) coronal
view and (C) sagittal view. Note the elongating gadolinium enhancing band-like area adjacent to the superomedial aspect of the left optic nerve sheath
compressing and displacing the optic nerve inferolaterally.
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performed (Fig. 2), which showed an elongating gadolinium
enhancing band-like area adjacent to the superomedial aspect
of the left optic nerve sheath measuring 13.4  3.5 mm,compressing and displacing the optic nerve inferolaterally.
The optic nerve did not appear to be involved. The mass
extended posteriorly to the level of the optic foramen. A cere-
bral angiogram was performed, which did not show a carotid
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an ONSM, a diffuse glioma of the optic nerve, or less likely,
an atypical recurrence of pituitary adenoma.
With her previous history of pituitary adenoma with radia-
tion treatment, progressing symptoms and the uncertainty of
the diagnosis, the patient expressed a strong preference for
surgical exploration and removal of the lesion with division of
the optic nerve rather than further radiation therapy. She was
aware that surgical exploration would leave her with no light
perception vision post-operatively.
A stereotactically guided resection of tumor was per-
formed through an orbitozygomatic craniotomy. The left
frontal lobe was gently retracted to expose the superior
orbit. The roof of the orbit was decompressed to 6 mm ante-
rior to the optic canal. After opening the periorbita and
exposing the muscle cone, the supraorbital nerve was mobi-
lized laterally. The optic nerve was localized behind the globe
and the optic nerve was full inside the dura. A band-like struc-
ture was not identified; instead, a macroscopically normal-
looking nerve was found surrounded by soft red/brown
material. Resection of the optic nerve over a 16 mm distance
was performed and sent for histopathology.
Histopathology (Fig. 3) showed fibrous thickening of the
dura and arachnoid around the nerve with large collections of
meningiothelial cells between the two layers with occasional
psammoma bodies within the cellular collections. The
meningiothelial cells show immunoperoxidase staining for pro-
gesterone receptors with a negligible proliferation rate with
virtually no staining for Ki67. Taken altogether, this was consis-
tent with an ONSM. No invasion of the optic nerve was noted.
No subdural involvementof themeningiomawas seenat either
end of the nerve segment. Thus far, the patient has been
followed up over a 12 month period and is recovering well.
Discussion
Our case demonstrated unusual radiological features of a
histologically confirmed ONSM. The largest case series on
record of ONSM describes five radiological patterns com-
monly encountered.2 The commonest pattern identified
was tubular (62% of cases), with subgroups of diffuse (45%),
apical expansion (15%) and anterior expansion (3%), which
had minimal widening of the optic nerve and more frequentFigure 3. Histological appearance of the optic nerve sheath meningioma.
The meningiothelial cells do not invade the pial/arachnoid tissue.
(Hematoxylin and eosin stain.)evidence of calcification.2 The second group was globular
tumors (23%) where growth was outside the dural sheath
causing significant proptosis. 11% displayed a fusiform pat-
tern and 4% had a focal enlargement of the optic nerve.2
The radiological appearance of the ONSM in our case did
not conform to any of the known patterns; rather, it appeared
as a distinct band-like structure that displaced the optic
nerve.
Previous ionizing radiation is a known cause of ONSM.4,5
Such secondary meningiomas tend to present at a younger
age, present with multiple lesions commonly arising from
the sphenoid ridge, tuberculum sellae or olfactory groove
and demonstrate a higher recurrence rate.4,6,7 Histopathol-
ogy also suggests that they tend to be more aggressive, with
a higher tendency toward malignancy in patients who had
high nose radiation therapy.4,8 This knowledge played a role
in the decision made by our well-informed patient.
Canalicular ONSM can often pose a diagnostic challenge
for clinicians as very small lesions can compress the optic
nerve and cause significant and progressive visual symptoms
because the bony canal walls limit expansion. Reports have
shown diagnostic delays of greater than 1 year due to this
variability in radiological appearance.4 It is strongly recom-
mended that all cases of progressive visual loss be investi-
gated by high-spatial-resolution MR of the orbit before and
after contrast enhancement in combination with fat
suppression.4,5
Recent literature reviews support the safety of fraction-
ated radiotherapy in the treatment of ONSM.2,3
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